Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394576 | PMC |
| http://dx.doi.org/10.1038/s42003-025-08665-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modified pro re nata regimen of brolucizumab in treatment-naive neovascular age-related macular degeneration.
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
Correction: Adaptive dynamic ϵ-simulated annealing algorithm for tumor immunotherapy.
Front Immunol
August 2025
Department of Gynaecology, Laoning Cancer Hospital and Institute, Shenyang, China.
[This corrects the article DOI: 10.3389/fimmu.2025.
View Article and Find Full Text PDFCorrection: Shared diagnostic genes and potential mechanism between PCOS and recurrent implantation failure revealed by integrated transcriptomic analysis and machine learning.
Front Immunol
August 2025
Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
[This corrects the article DOI: 10.3389/fimmu.2023.
View Article and Find Full Text PDFCorrection: BCG and beyond: unlocking new frontiers in TB vaccine development.
Front Immunol
August 2025
Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
[This corrects the article DOI: 10.3389/fimmu.2025.
View Article and Find Full Text PDF[This corrects the article DOI: 10.17816/CP15491.].
View Article and Find Full Text PDF